Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio

(STL.News) – Pfizer Inc. (NYSE: PFE) is presenting data across its industry-leading oncology portfolio, including company-sponsored and collaborative research studies, spanning 11 therapies in 22 types of cancer, at the European Society for Medical Oncology (ESMO) Congress to be held in Barcelona, Spain, September 27 – October 1, 2019.  Data from nearly 50 abstracts involving Pfizer cancer medicines will illustrate the diversity of the portfolio and the company’s cutting-edge scientific approach.  For the first time, this will include data presentations on compounds from the acquisition of Array Biopharma Inc.

“At this year’s ESMO Congress, we’re looking forward to showcasing how we’re embodying ESMO’s theme of translating science into better patient care,” said Chris Boshoff, M.D., Ph.D., Chief Development Officer, Oncology, Pfizer Global Product Development.  “Whether it’s studying patient populations such as those affected by BRAF-mutant metastatic colorectal cancerwho are in need of new treatment options, utilizing new techniques like real-world evidence to understand further the impact of our medicines in the non-clinical trial setting, or studying a different way to administer a treatment that may be more convenient for patients, Pfizer is leading the way in taking innovative approaches to meeting the needs of people living with cancer.”

Clinical data can be complex and often difficult to understand if a person is not a scientist.  To help interested non-scientists better understand the latest research, Pfizer developed summaries in non-technical language for research results being presented at this year’s ESMO Congress.  These informational materials, called “abstract plain language summaries (APLS),” will be made available for non-scientists to learn more about Pfizer’s latest scientific developments.